Over the past two years, GLP-1 receptor agonists, Ozempic, Wegovy, Mounjaro, have reshaped the healthcare landscape. These drugs are not just diet aids; they represent a paradigm shift in obesity management, diabetes care, and even cardiovascular risk reduction. They are, by every measure, blockbuster medicines. But success has brought
August played out almost exactly as projected. The S&P 500 rose 1.9% for the month, versus the model’s forecast of +1.5%. The Dow climbed 3.2% as UnitedHealth reversed course and rebounded. The Russell 2000 outperformed as breadth returned to the market, just as anticipated.
We believe structural changes under new U.S. policies are setting the stage for the next leg of one of the greatest bull markets in history. The Clarity Act, the new FASB accounting rules effective in 2025, and the introduction of a 2.5% in-kind trade tax are catalysts
The rise of cryptocurrency has rapidly moved from the fringes of finance into the very center of global capital markets. The launch of spot Bitcoin and Ethereum ETFs on U.S. exchanges such as the NYSE, Nasdaq, and CBOE has fundamentally changed how institutions, asset managers, and retail investors access
Modern farming has come to rely heavily on herbicides and fungicides, with glyphosate, marketed as Roundup, being the most widely used. The prevailing narrative is that the danger lies in chemical residues left on food, but the deeper and more insidious problem is what these chemicals do to the plants
The male fertility crisis is a growing, invisible epidemic that threatens future generations. While many people believe that the declining rates of reproduction are simply a lifestyle choice, an increasing number of people opting out of having children, the reality is far darker. The cause isn't a conscious
In February, I argued that 2025 would rhyme with 1926 — the year when a volatile, skeptical market finally launched into the vertical phase of one of history’s greatest bull runs. That view has only strengthened as the months pass. July landed close to my forecast of ~4% gains, with
Over the past two decades, rates of early-onset cancers have climbed at an alarming pace. Young adults under 50 are being diagnosed with colon, pancreatic, breast, and brain cancers at rates not seen in previous generations. While lifestyle changes and processed food consumption are frequently blamed, a growing body
Non‑alcoholic fatty liver disease (NAFLD) and alcoholic liver disease (ALD) have emerged as silent epidemics in the United States, affecting tens of millions of people, often without symptoms until advanced stages. These conditions do not develop in a vacuum. Instead, they are driven by a complex interplay between genetics,
In February, I wrote that 2025 would rhyme with 1926, the year when a volatile, skeptical market finally launched into the vertical phase of one of history’s greatest bull runs. By mid-year, that forecast has held: the spring correction shook out the weak hands, and U.S. equities
Over the past two decades, breast cancer has surged in unexpected ways—particularly among young Asian American women. Once considered a lower-risk group, Asian American and Pacific Islander (AAPI) women are now seeing some of the fastest increases in breast cancer incidence in the United States. According to recent
Over the past 15 years, early-onset colorectal cancer (EOCRC), once a medical rarity, has exploded into a global public health crisis. Rates are climbing across nearly every major country, particularly among individuals aged 15 to 40. In fact, colorectal cancer is now on track to become the most diagnosed